AMRN AMARIN CORP PLC\UK
Pharmaceutical Preparations · Nasdaq · SEC CIK 897448 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-22.3%
TTM net income YoY77.8%
TTM EPS YoY81.0%
Revenue 3-yr CAGR-18.3%
Net income 3-yr CAGR—
Margins
Gross margin40.9%
Operating margin-18.2%
Net margin-10.9%
FCF margin—
EBITDA margin—
Returns
ROE-4.2%
ROA-3.0%
ROIC (approx.)-8.1%
Asset turnover0.27x
Leverage & solvency
Liabilities / assets29.9%
Debt / equity0.00x
Current ratio3.50x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.96x
Accruals ratio-8.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $39.55M | $42.21M | $45.13M | $49.22M | $49.67M | $72.74M | $42.02M | $62.31M |
| Gross profit | $16.18M | $14.99M | $17.77M | $23.17M | $22.21M | $50.36M | $25.13M | -$9.57M |
| R&D expense | $4.21M | $4.77M | $4.67M | $5.37M | $4.21M | $4.92M | $5.31M | $5.99M |
| SG&A expense | $14.34M | $22.19M | $21.11M | $20.06M | $19.70M | $38.67M | $36.57M | $36.97M |
| Operating income | -$2.36M | -$12.01M | -$11.33M | -$6.33M | -$11.10M | -$15.98M | -$16.75M | -$52.52M |
| Pretax income | $315,000 | -$7.87M | -$8.72M | -$852,000 | -$8.12M | -$13.45M | -$13.63M | -$49.91M |
| Income tax | $70,000 | -$219,000 | $1.79M | $372,000 | -$377,000 | $689,000 | $2.07M | -$1.29M |
| Net income | $245,000 | -$7.65M | -$10.51M | -$1.22M | -$7.74M | -$14.14M | -$15.70M | -$48.62M |
| EPS (basic) | 0.00 | -0.02 | -0.03 | — | -0.02 | -0.03 | -0.04 | — |
| EPS (diluted) | 0.00 | -0.02 | -0.03 | — | -0.02 | -0.03 | -0.04 | — |
| Weighted avg. shares (diluted) | 427.86M | 416.44M | 419.05M | — | 415.53M | 414.48M | 413.42M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $156.51M | $143.56M | $131.06M | $134.66M | $122.80M | $147.88M | $119.52M | $121.04M |
| Short-term investments | $166.87M | $171.09M | $176.76M | $167.93M | $163.78M | $150.83M | $162.26M | $173.18M |
| Receivables | $111.57M | $92.92M | $108.05M | $126.83M | $127.31M | $119.13M | $106.73M | $122.28M |
| Inventory | $158.85M | $164.07M | $183.59M | $195.91M | $184.70M | $171.24M | $159.49M | $166.05M |
| Current assets | $612.88M | $602.76M | $626.02M | $649.88M | $628.33M | $606.82M | $573.06M | $595.40M |
| PP&E, net | — | — | — | $12,000 | $13,000 | $14,000 | $15,000 | $16,000 |
| Intangibles | $11.46M | $12.09M | $12.73M | $13.37M | $14.07M | $14.93M | $15.66M | $16.39M |
| Total assets | $634.08M | $624.36M | $645.76M | $670.77M | $659.81M | $670.13M | $655.68M | $685.35M |
| Current liabilities | $175.14M | $164.19M | $179.64M | $194.46M | $182.23M | $185.95M | $162.41M | $179.95M |
| Total liabilities | $189.67M | $180.75M | $196.35M | $211.49M | $200.92M | $205.20M | $181.99M | $199.17M |
| Shareholders' equity | $444.41M | $443.62M | $449.41M | $459.28M | $458.89M | $464.92M | $473.69M | $486.18M |
| Shares outstanding | 421.63M | 420.04M | 419.59M | 416.21M | 415.97M | 415.40M | 414.37M | 411.58M |
| Cash flow statement | ||||||||
| Operating cash flow | $9.22M | $6.60M | $6.39M | $15.28M | -$12.70M | $16.61M | -$12.46M | -$13.31M |
| Investing cash flow | $4.56M | $6.14M | -$8.30M | -$3.52M | -$12.13M | $12.41M | $12.06M | -$22.84M |
| Financing cash flow | -$826,000 | -$247,000 | -$1.69M | -$4,000 | -$248,000 | -$663,000 | -$1.12M | $17,000 |
| Stock-based compensation | $1.38M | $2.10M | $2.33M | $1.61M | $1.96M | $6.04M | $4.33M | $3.40M |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.